Zacks • yesterday
Genomic Health, Inc. (GHDX) reported fourth-quarter 2016 earnings per share of 4 cents, reflecting an improvement from the year-ago quarter's loss figure of 8 cents.
Associated Press • 2 days ago
On a per-share basis, the Redwood City, California-based company said it had profit of 4 cents. The results exceeded Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...
Capital Cube • 2 months agoGenomic Health, Inc. breached its 50 day moving average in a Bearish Manner : GHDX-US : December 20, 2016
Categories: ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Genomic Health, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more (Read more...)
Insider Monkey • 2 months ago
Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals. They generate significant returns for investors to justify their large fees and they allocate a lot of time and employ a complex analysis to determine the best stocks to invest in. A particularly […]
Zacks • 2 months ago
Genomic Health Inc. (GHDX) recently unveiled positive findings of its Oncotype DX test in individualizing breast cancer treatment decisions for patients at various stages of the disease.
Zacks • 2 months ago
Myriad Genetics (MYGN) released favorable study results demonstrating the superiority of EndoPredict test over Oncotype Dx on long-term recurrence of breast cancer.
GHDX : Summary for Genomic Health, Inc. - Yahoo Finance
Genomic Health, Inc. (GHDX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Day's Range||30.29 - 31.15|
|52 Week Range||22.00 - 33.96|
|PE Ratio (TTM)||-55.37|
|Earnings Date||May 2, 2017 - May 8, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||31.57|